Your browser doesn't support javascript.
loading
Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism.
Strobelt, Romano; Adler, Julia; Paran, Nir; Yahalom-Ronen, Yfat; Melamed, Sharon; Politi, Boaz; Shulman, Ziv; Schmiedel, Dominik; Shaul, Yosef.
Affiliation
  • Strobelt R; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
  • Adler J; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
  • Paran N; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Yahalom-Ronen Y; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Melamed S; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Politi B; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Shulman Z; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Schmiedel D; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Shaul Y; Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Sci Rep ; 12(1): 5758, 2022 04 06.
Article in En | MEDLINE | ID: mdl-35388061
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: En Journal: Sci Rep Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: En Journal: Sci Rep Year: 2022 Document type: Article